Evaluation of 99mTc-immunoglobulins for imaging infection in the rat

被引:1
作者
Tsopelas, Chris
Penglis, Stan
Miller, Darren
Rischmueller, Maureen
Dylan, F.
Bartholomeusz, L.
机构
[1] Royal Adelaide Hosp, Dept Nucl Med, RAH Radiopharm, Adelaide, SA 5000, Australia
[2] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA 5005, Australia
[3] Queen Elizabeth Hosp, Dept Rheumatol, Adelaide, SA, Australia
关键词
immunoglobulin; 99mTc; infection imaging;
D O I
10.1002/jlcr.1108
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Three immunoglobulin molecules were evaluated as infection imaging agents in a rat model of S. aureas infection: Tc-99m-infliximab, Tc-99m-human immunoglobulin (HIG) and Tc-99m-rat immunoglobulin (RIG). Infliximab is a chimeric monoclonal antibody specific for human tumour necrosis factor alpha (TNF alpha). Tc-99m-HIG was chosen as an exogenous protein and Tc-99m-RIG as an endogenous marker. Each immunoglobulin was treated with 2-mercaptoethanol and the reduced antibody was isolated by size exclusion chromatography. In combination with Sn-II-methylenediphosphonic acid, cold kit formulations were prepared. Native and reduced infliximab were tested for rat TNF alpha binding ability in vitro. A focal intramuscular infection of S. aureus (1 x 10(8) colony forming units) was induced in the left thigh muscle of rats, that developed for 24h. In separate experiments each tracer was administered by intravenous injection, then whole body scintigraphic imaging and biodistribution studies were performed at 1 and 4h later. Tc-99m-infliximab, Tc-99m-HIG and Tc-99m-RIG were prepared with >= 95% radiochemical purity from stable cold kits. Results from the organ assay gave infected (target) to non-infected (control) muscle ratios for Tc-99m-infliximab as 5.7 +/- 0.8, 7.1 +/- 1.2, Tc-99m-HIG gave 3.1 +/- 1.1, 7.8 +/- 1.2, and Tc-99m-RIG 7.9 +/- 0.3, 12.5 +/- 1.5 at 1 and 4 h, respectively. Infliximab and Sn-II-infliximab did not bind to rat TNF alpha by the in vitro assay. Although lacking specific affinity for TNF alpha, Tc-99m-infliximab accumulated at infectious sites in vivo. Tc-99m-infliximab gave similar infection uptake ratios to Tc-99m-HIG at 1 and 4h, but these proteins were inferior in comparison to Tc-99m-RIG, and is likely to be due to increased clearance associated with the foreign protein structure. Copyright (c) 2006 John Wiley & Sons, Ltd.
引用
收藏
页码:915 / 928
页数:14
相关论文
共 38 条
  • [1] Dual radiolabeled liposomes: Biodistribution studies and localization of focal sites of infection in rats
    Awasthi, VD
    Goins, B
    Klipper, R
    Phillips, WT
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (02) : 155 - 160
  • [2] BAKER R, 1989, TECHNETIUM RHENIUM C, V3, P741
  • [3] Scintigraphic imaging using 99mTc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats
    Becker, MJ
    Dams, ETM
    de Marie, S
    Oyen, WJG
    Boerman, OC
    Fens, MHAM
    Verbrugh, HA
    Bakker-Woudenberg, IAJM
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 2002, 29 (02) : 177 - 184
  • [4] Boonkitticharoen Vipa, 2001, Journal of the Medical Association of Thailand, V84, P545
  • [5] DEVELOPMENT OF A DEXTRAN KIT FOR LABELING WITH TC-99M AND ITS EVALUATION FOR LYMPHOSCINTIGRAPHY
    DASS, RS
    SINGH, AK
    CHAUHAN, UPS
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1993, 20 (05): : 701 - 706
  • [6] ACCUMULATION OF SOME SMALL MOLECULAR-WEIGHT COMPLEXES OF TC-99M IN EXPERIMENTAL ABSCESSES
    ERCAN, MT
    UNLENEN, E
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1994, 21 (02): : 143 - 149
  • [7] FISCHMAN AJ, 1990, J NUCL MED, V31, P1199
  • [8] FISCHMAN AJ, 1992, J NUCL MED, V33, P1378
  • [9] 99mTc-E-selectin binding peptide for imaging acute osteomyelitis in a novel rat model
    Gratz, S
    Béhé, M
    Boerman, OC
    Kunze, E
    Schulz, H
    Eiffert, H
    O'Reilly, T
    Behr, TM
    Angerstein, C
    Nebendahl, K
    Kauer, F
    Becker, W
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2001, 22 (09) : 1003 - 1013
  • [10] Role of 99mTc Sulesomab in the diagnosis of prosthetic joint infections
    Iyengar, KR
    Vinjamuri, S
    [J]. NUCLEAR MEDICINE COMMUNICATIONS, 2005, 26 (06) : 489 - 496